Page 2 - Sandrad Angelo News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Responses observed across a broad range of antigen expression - Initial safety and durability are encouraging - PHILADELPHIA, PA., and OXFORDSHIRE, U.K., May 20, 2021 Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, will report initial data from its Phase 2 SPEARHEAD-1 trial, with afamitresgene autoleucel (afami-cel, formerly ADP-A2M4), at the American Society of Clinical Oncology (ASCO) congress. Full abstracts were released online today. Data will be presented in an oral presentation by Dr. Sandra D Angelo of the Memorial Sloan Kettering Cancer Center (Abstract #11504) on June 4th. Patients are seeing substantial benefit from afami-cel in SPEARHEAD-1 across a broad range of cell doses and levels of MAGE-A4 expression, said Adrian Rawcliffe, Adaptimmune Chief Executive Officer. We have shown a high response rate and these responses are still evolving in many patients with increasing depths of response over time and encouraging durability

United statesAdrian rawcliffeJulip millerSandra dangeloExchange commissionAmerican society of clinical oncologyMemorial sloan kettering cancer centerAmerican societyClinical oncologySandrad angeloAdaptimmune chief executiveMemorial sloan kettering cancerSpecific peptide enhanced affinity receptorPrivate securities litigation reform actQuarterly reportInvestor relations